Analyst Ratings and Valuation Comparison for Haleon and BioHarvest Sciences
What happened
MarketBeat compared the consumer staples companies Haleon and BioHarvest Sciences based on earnings, risk, and valuation. Haleon reported higher revenue and earnings than BioHarvest Sciences. Haleon has 6.7% institutional ownership, while BioHarvest Sciences has a beta of 1.04, indicating it is 4% more volatile than the S&P 500.
From themarketsdaily.com
Why it matters
The comparison highlights differences in risk and valuation between the two companies. BioHarvest Sciences currently trades at a lower price-to-earnings ratio than Haleon. MarketBeat reported a consensus target price of $6.50 for BioHarvest Sciences and $4.90 for Haleon.
From themarketsdaily.com
Who's involved
- MarketBeatReported the analyst recommendations and financial comparison.
- HaleonA consumer staples company whose financial metrics were compared.
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
- MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
- BlackRock and Dimensional Fund Advisors increased their stakes in Strattec Security, with MarketBeat reporting related stock data.
-
Haleon
British multinational consumer healthcare company
Nothing else this week.
Related events
- MarketBeat provides analyst recommendations and compares FAT Brands and Centerra Gold as materials companies.
- MarketBeat provided analyst ratings for CPS Technologies Corp. on October 22, 2026.
- MarketBeat reported analyst recommendations for small-cap finance companies Perella Weinberg Partners and Fidus Investment.
- MarketBeat reported analyst recommendations for small-cap technology companies Energous Corporation and Magnachip Semiconductor.
- MarketBeat reports analyst recommendations for finance companies First Bancorp and Bankwell Financial Group.